{"changeSha256":"a39b79b16a6eb66c84b61281c42bde8e0f424d6f2b2373e2751a26779bb56021","changedAt":"2026-11-14","changedFields":[{"after":"In clinical trials; not FDA-approved","before":"Investigational","field":"Status"},{"after":"An experimental Altimmune glucagon and GLP-1 receptor agonist studied in the liver disease MASH. It is not FDA-approved.","before":"A glucagon/GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.","field":"Profile summary"},{"after":"A 24-week randomized Phase 2 trial met its MASH-resolution goal but not its fibrosis goal. A Phase 3 trial in MASH was recruiting in August 2026.","before":"ClinicalTrials.gov lists Altimmune's IMPACT study as completed, last updated May 18, 2026.","field":"Evidence note"},{"after":"ctg-nct05989711-v10, journal-pmid-41237796, ctg-observation-nct07795164-2026-08-31-445923515599, ctg-observation-nct06987513-2026-07-31-1e0339600b69, ctg-observation-nct07009860-2026-03-20-c02a1977625c","before":"ctg-nct05989711-v10","field":"Cited source records"},{"after":"name: ctg-nct05989711-v10; aliases: ctg-nct05989711-v10; category: ctg-nct05989711-v10; status: ctg-nct05989711-v10, ctg-observation-nct07795164-2026-08-31-445923515599; summary: ctg-nct05989711-v10, journal-pmid-41237796; evidenceNote: journal-pmid-41237796, ctg-observation-nct07795164-2026-08-31-445923515599","before":"name: ctg-nct05989711-v10; aliases: ctg-nct05989711-v10; category: ctg-nct05989711-v10; status: ctg-nct05989711-v10; summary: ctg-nct05989711-v10; evidenceNote: ctg-nct05989711-v10","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/pemvidutide/versions/3/","version":3},"id":"profile:pemvidutide:v3","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, IMPACT trial results from our human evidence review, and retained ClinicalTrials.gov records for later trials, including a Phase 3 trial in MASH.","peptideSlugs":["pemvidutide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/pemvidutide/v2.json","sha256":"19d3937b0c904a968de5a04cc518f3fdbe20a4084105fa0791542bdc7e680112"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/pemvidutide/versions/2/","version":2},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"journal-pmid-41237796","name":"The Lancet","sourceClass":"A","title":"Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study (2025) · PMID 41237796","url":"https://doi.org/10.1016/S0140-6736(25)02114-2","verifiedAt":"2026-11-14"},{"id":"ctg-observation-nct07795164-2026-08-31-445923515599","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT07795164 · retained source version 2026-08-31:445923515599b1c75e5a12a2ec64209d4453be7d93d0614bca15d8035020d448","url":"https://clinicaltrials.gov/study/NCT07795164","verifiedAt":"2026-09-09"}],"subject":{"slug":"pemvidutide","type":"profile"}}
